Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-08165784
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-08165784 is an orally administered small molecule inhibitor targeting phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA). Developed by Pfizer, the drug is designed to treat advanced or metastatic solid tumors harboring PIK3CA mutations, including hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer and colorectal cancer. By selectively inhibiting PIK3CA, PF-08165784 blocks the hyperactive PI3K/Akt/mTOR signaling pathway that drives tumor cell proliferation and survival. It is currently being evaluated in Phase 1 clinical trials as a monotherapy and in combination with other anti-cancer agents such as fulvestrant, letrozole, cetuximab, and atirmociclib.
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on PF-08165784.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-08165784.